A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the
Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102
Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic
Conjunctivitis.